;PMID: 10510729 ;source_file_1212.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..39] = [t:0..39] ;1)sentence:[e:44..178] = [t:44..178] ;2)section:[e:182..242] = [t:182..242] ;3)section:[e:246..351] = [t:246..351] ;4)sentence:[e:355..475] = [t:355..475] ;5)sentence:[e:476..683] = [t:476..683] ;6)sentence:[e:684..804] = [t:684..804] ;7)sentence:[e:805..938] = [t:805..938] ;8)sentence:[e:939..1178] = [t:939..1178] ;9)sentence:[e:1179..1382] = [t:1179..1382] ;10)sentence:[e:1383..1459] = [t:1383..1459] ;11)sentence:[e:1460..1633] = [t:1460..1633] ;12)sentence:[e:1634..1774] = [t:1634..1774] ;13)section:[e:1778..1823] = [t:1778..1823] ;section 0 Span:0..39 ;Clin Chem Lab Med 1999 Jul;37(7):723-7 (SEC (FRAG (NNP:[0..4] Clin) (NNP:[5..9] Chem) (NNP:[10..13] Lab) (NNP:[14..17] Med) (CD:[19..23] 1999) (.:[24..31] Jul;37-LRB-) (CD:[31..33] 7-RRB-) (CD:[33..37] :723) (HYPH:[37..38] -) (CD:[38..39] 7))) ;sentence 1 Span:44..178 ;A relationship between K-ras gene mutations and some clinical and histologic ;variables in patients with primary colorectal carcinoma. ;[67..72]:gene-rna:"K-ras" ;[149..177]:malignancy:"primary colorectal carcinoma" (SENT (NP-HLN (NP (DT:[44..45] A) (NN:[46..58] relationship)) (PP (IN:[59..66] between) (NP (NP (NN:[67..72] K-ras) (NN:[73..77] gene) (NNS:[78..87] mutations)) (CC:[88..91] and) (NP (NP (DT:[92..96] some) (ADJP (JJ:[97..105] clinical) (CC:[106..109] and) (JJ:[110..120] histologic)) (NNS:[122..131] variables)) (PP (IN:[132..134] in) (NP (NP (NNS:[135..143] patients)) (PP (IN:[144..148] with) (NP (JJ:[149..156] primary) (JJ:[157..167] colorectal) (NN:[168..177] carcinoma)))))))) (.:[177..178] .))) ;section 2 Span:182..242 ;Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E. (SEC (FRAG (NNP:[182..189] Beranek) (NNP:[190..192] M,) (NNP:[193..198] Bures) (NNP:[199..201] J,) (NNP:[202..209] Palicka) (NNP:[210..211] V) (,:[211..212] ,) (NNP:[213..219] Jandik) (NNP:[220..221] P) (,:[221..222] ,) (NNP:[223..228] Langr) (NNP:[229..230] F) (,:[230..231] ,) (NNP:[232..239] Nejedla) (NNP:[240..242] E.))) ;section 3 Span:246..351 ;Institute of Clinical Biochemistry and Diagnostics, University Hospital, ;Hradec Kralove, Czech Republic. (SEC (FRAG (NNP:[246..255] Institute) (IN:[256..258] of) (NNP:[259..267] Clinical) (NNP:[268..280] Biochemistry) (CC:[281..284] and) (NNP:[285..296] Diagnostics) (,:[296..297] ,) (NNP:[298..308] University) (NNP:[309..317] Hospital) (,:[317..318] ,) (NNP:[319..325] Hradec) (NNP:[327..334] Kralove) (,:[334..335] ,) (NNP:[336..341] Czech) (NNP:[342..350] Republic) (.:[350..351] .))) ;sentence 4 Span:355..475 ;Mutations in the Kirsten ras 2 (K-ras) gene were described as early events in ; the process of colorectal carcinogenesis. ;[372..385]:gene-rna:"Kirsten ras 2" ;[387..392]:gene-rna:"K-ras" (SENT (S (NP-SBJ-1 (NP (NNS:[355..364] Mutations)) (PP (IN:[365..367] in) (NP (DT:[368..371] the) (NML (NML (NNP:[372..379] Kirsten) (NN:[380..383] ras) (CD:[384..385] 2)) (NML (-LRB-:[386..387] -LRB-) (NN:[387..392] K-ras) (-RRB-:[392..393] -RRB-))) (NN:[394..398] gene)))) (VP (VBD:[399..403] were) (VP (VBN:[404..413] described) (NP-1 (-NONE-:[413..413] *)) (PP (IN:[414..416] as) (NP (NP (JJ:[417..422] early) (NNS:[423..429] events)) (PP (IN:[430..432] in) (NP (NP (DT:[434..437] the) (NN:[438..445] process)) (PP (IN:[446..448] of) (NP (JJ:[449..459] colorectal) (NN:[460..474] carcinogenesis))))))))) (.:[474..475] .))) ;sentence 5 Span:476..683 ;The aim of this study was to find a possible relationship between the ;presence of K-ras mutation in samples of primary colorectal carcinomas and ;the clinico-pathological data of the investigated patients. ;[559..564]:gene-rna:"K-ras" ;[589..618]:malignancy:"primary colorectal carcinomas" (SENT (S (NP-SBJ (NP (DT:[476..479] The) (NN:[480..483] aim)) (PP (IN:[484..486] of) (NP (DT:[487..491] this) (NN:[492..497] study)))) (VP (VBD:[498..501] was) (S-PRD (NP-SBJ (-NONE-:[501..501] *)) (VP (TO:[502..504] to) (VP (VB:[505..509] find) (NP (NP (DT:[510..511] a) (JJ:[513..521] possible) (NN:[522..534] relationship)) (PP (IN:[535..542] between) (NP (NP (NP (DT:[543..546] the) (NN:[547..555] presence)) (PP (IN:[556..558] of) (NP (NN:[559..564] K-ras) (NN:[565..573] mutation))) (PP-LOC (IN:[574..576] in) (NP (NP (NNS:[577..584] samples)) (PP (IN:[585..587] of) (NP (JJ:[589..596] primary) (JJ:[597..607] colorectal) (NNS:[608..618] carcinomas)))))) (CC:[619..622] and) (NP (NP (DT:[623..626] the) (ADJP (AFX:[627..634] clinico) (HYPH:[634..635] -) (JJ:[635..647] pathological)) (NNS:[648..652] data)) (PP (IN:[653..655] of) (NP (DT:[656..659] the) (VBN:[661..673] investigated) (NNS:[674..682] patients))))))))))) (.:[682..683] .))) ;sentence 6 Span:684..804 ;Mutation in codon 12 of the K-ras gene was determined in 18 of 53 colorectal ;carcinomas (34%) in our group of patients. ;[696..704]:variation-location:"codon 12" ;[712..717]:gene-rna:"K-ras" ;[751..772]:malignancy:"colorectal carcinomas" (SENT (S (NP-SBJ-1 (NP (NN:[684..692] Mutation)) (PP-LOC (IN:[693..695] in) (NP (NP (NN:[696..701] codon) (CD:[702..704] 12)) (PP (IN:[705..707] of) (NP (DT:[708..711] the) (NN:[712..717] K-ras) (NN:[718..722] gene)))))) (VP (VBD:[723..726] was) (VP (VBN:[727..737] determined) (NP-1 (-NONE-:[737..737] *)) (PP (IN:[738..740] in) (NP (NP (CD:[742..744] 18)) (PP (IN:[745..747] of) (NP (CD:[748..750] 53) (JJ:[751..761] colorectal) (NNS:[762..772] carcinomas))) (PRN (-LRB-:[773..774] -LRB-) (NP (CD:[774..776] 34) (NN:[776..777] %)) (-RRB-:[777..778] -RRB-)))) (PP (IN:[779..781] in) (NP (NP (PRP$:[782..785] our) (NN:[786..791] group)) (PP (IN:[792..794] of) (NP (NNS:[795..803] patients))))))) (.:[803..804] .))) ;sentence 7 Span:805..938 ;The presence of K-ras gene mutations was not related to gender, age of ;subject at diagnosis, staging or cancer location (p > 0.05). ;[822..827]:gene-rna:"K-ras" (SENT (S (NP-SBJ-1 (NP (DT:[805..808] The) (NN:[809..817] presence)) (PP (IN:[818..820] of) (NP (NN:[822..827] K-ras) (NN:[828..832] gene) (NNS:[833..842] mutations)))) (VP (VBD:[843..846] was) (RB:[847..850] not) (VP (JJ:[851..858] related) (NP-1 (-NONE-:[858..858] *)) (PP-CLR (TO:[859..861] to) (NP (NP (NN:[862..868] gender)) (,:[868..869] ,) (NP (NP (NN:[870..873] age)) (PP (IN:[874..876] of) (NP (NN:[877..884] subject))) (PP-TMP (IN:[885..887] at) (NP (NN:[888..897] diagnosis)))) (,:[897..898] ,) (NP (NN:[900..907] staging)) (CC:[908..910] or) (NP (NN:[911..917] cancer) (NN:[918..926] location) (PRN (-LRB-:[927..928] -LRB-) (S (NP-SBJ (NN:[928..929] p)) (VP (SYM:[930..931] >) (NP (CD:[932..936] 0.05)))) (-RRB-:[936..937] -RRB-))))))) (.:[937..938] .))) ;sentence 8 Span:939..1178 ;Sixteen of the 42 (38%) moderately differentiated carcinomas, and two of the ;eight (25%) well differentiated carcinomas contained K-ras mutation in codon ;12, but none of the three poorly differentiated carcinomas contained the ;mutation. ;[963..1000]:malignancy:"moderately differentiated carcinomas" ;[1029..1060]:malignancy:"well differentiated carcinomas" ;[1071..1076]:gene-rna:"K-ras" ;[1089..1097]:variation-location:"codon 12" ;[1121..1154]:malignancy:"poorly differentiated carcinomas" ;[1169..1177]:variation-event:"mutation" (SENT (S (NP-SBJ (NP (NP (CD:[939..946] Sixteen)) (PP (IN:[947..949] of) (NP (DT:[950..953] the) (CD:[954..956] 42) (PRN (-LRB-:[957..958] -LRB-) (NP (CD:[958..960] 38) (NN:[960..961] %)) (-RRB-:[961..962] -RRB-)) (ADJP (RB:[963..973] moderately) (VBN:[975..989] differentiated)) (NNS:[990..1000] carcinomas)))) (,:[1000..1001] ,) (CC:[1002..1005] and) (NP (NP (CD:[1006..1009] two)) (PP (IN:[1010..1012] of) (NP (DT:[1013..1016] the) (CD:[1017..1022] eight) (PRN (-LRB-:[1023..1024] -LRB-) (NP (CD:[1024..1026] 25) (NN:[1026..1027] %)) (-RRB-:[1027..1028] -RRB-)) (ADJP (RB:[1029..1033] well) (VBN:[1034..1048] differentiated)) (NNS:[1050..1060] carcinomas))))) (VP (VBD:[1061..1070] contained) (NP (NP (NN:[1071..1076] K-ras) (NN:[1077..1085] mutation)) (PP-LOC (IN:[1086..1088] in) (NP (NN:[1089..1094] codon) (CD:[1095..1097] 12)))))) (,:[1097..1098] ,) (CC:[1099..1102] but) (S (NP-SBJ (NP (NN:[1103..1107] none)) (PP (IN:[1108..1110] of) (NP (DT:[1111..1114] the) (CD:[1115..1120] three) (ADJP (RB:[1121..1127] poorly) (VBN:[1129..1143] differentiated)) (NNS:[1144..1154] carcinomas)))) (VP (VBD:[1155..1164] contained) (NP (DT:[1165..1168] the) (NN:[1169..1177] mutation)))) (.:[1177..1178] .)) ;ERROR_Sentence has multiple children (TB Error):[939..1178]::S:,:CC:S:.: ;sentence 9 Span:1179..1382 ;Moderately differentiated tumours contained an aspartate code GAT (in eight ;cases), a valine code GTT (in six cases), an alanine code GCT (in one case) ;and a serine code AGT (in one case) in codon 12. ;[1179..1213]:malignancy:"Moderately differentiated tumours" ;[1227..1236]:variation-state-generic:"aspartate" ;[1242..1245]:variation-state-generic:"GAT" ;[1266..1272]:variation-state-generic:"valine" ;[1278..1281]:variation-state-generic:"GTT" ;[1302..1309]:variation-state-generic:"alanine" ;[1315..1318]:variation-state-generic:"GCT" ;[1339..1345]:variation-state-generic:"serine" ;[1351..1354]:variation-state-generic:"AGT" ;[1373..1381]:variation-location:"codon 12" (SENT (S (NP-SBJ (ADJP (RB:[1179..1189] Moderately) (VBN:[1190..1204] differentiated)) (NNS:[1206..1213] tumours)) (VP (VBD:[1214..1223] contained) (NP (NP (DT:[1224..1226] an) (NML (NML (NN:[1227..1236] aspartate) (NN:[1237..1241] code)) (NML (NN:[1242..1245] GAT))) (PRN (-LRB-:[1246..1247] -LRB-) (PP (IN:[1247..1249] in) (NP (CD:[1250..1255] eight) (NNS:[1256..1261] cases))) (-RRB-:[1261..1262] -RRB-))) (,:[1262..1263] ,) (NP (DT:[1264..1265] a) (NML (NML (NN:[1266..1272] valine) (NN:[1273..1277] code)) (NML (NN:[1278..1281] GTT))) (PRN (-LRB-:[1282..1283] -LRB-) (PP (IN:[1283..1285] in) (NP (CD:[1287..1290] six) (NNS:[1291..1296] cases))) (-RRB-:[1296..1297] -RRB-))) (,:[1297..1298] ,) (NP (DT:[1299..1301] an) (NML (NML (NN:[1302..1309] alanine) (NN:[1310..1314] code)) (NML (NN:[1315..1318] GCT))) (PRN (-LRB-:[1319..1320] -LRB-) (PP (IN:[1320..1322] in) (NP (CD:[1323..1326] one) (NN:[1327..1331] case))) (-RRB-:[1331..1332] -RRB-))) (CC:[1333..1336] and) (NP (DT:[1337..1338] a) (NML (NML (NN:[1339..1345] serine) (NN:[1346..1350] code)) (NML (NN:[1351..1354] AGT))) (PRN (-LRB-:[1355..1356] -LRB-) (PP (IN:[1356..1358] in) (NP (CD:[1359..1362] one) (NN:[1364..1368] case))) (-RRB-:[1368..1369] -RRB-)))) (PP (IN:[1370..1372] in) (NP (NN:[1373..1378] codon) (CD:[1379..1381] 12)))) (.:[1381..1382] .))) ;sentence 10 Span:1383..1459 ;Well differentiated tumours contained only the valine code GTT (two cases). ;[1383..1410]:malignancy:"Well differentiated tumours" ;[1430..1436]:variation-state-generic:"valine" ;[1443..1446]:variation-state-generic:"GTT" (SENT (S (NP-SBJ (ADJP (RB:[1383..1387] Well) (VBN:[1388..1402] differentiated)) (NNS:[1403..1410] tumours)) (VP (VBD:[1411..1420] contained) (NP (RB:[1421..1425] only) (NML (DT:[1426..1429] the) (NN:[1430..1436] valine) (NN:[1437..1441] code)) (NML (NN:[1443..1446] GTT)) (PRN (-LRB-:[1447..1448] -LRB-) (NP (CD:[1448..1451] two) (NNS:[1452..1457] cases)) (-RRB-:[1457..1458] -RRB-)))) (.:[1458..1459] .))) ;sentence 11 Span:1460..1633 ;Our results show that the frequency of mutations in the K-ras gene in ;carcinomas in Central Europe is not different from the frequencies found in ;other parts of the world. ;[1516..1521]:gene-rna:"K-ras" ;[1531..1541]:malignancy:"carcinomas" (SENT (S (NP-SBJ (PRP$:[1460..1463] Our) (NNS:[1464..1471] results)) (VP (VBP:[1472..1476] show) (SBAR (IN:[1477..1481] that) (S (NP-SBJ (NP (DT:[1482..1485] the) (NN:[1486..1495] frequency)) (PP (IN:[1496..1498] of) (NP (NP (NNS:[1499..1508] mutations)) (PP (IN:[1509..1511] in) (NP (DT:[1512..1515] the) (NN:[1516..1521] K-ras) (NN:[1523..1527] gene))))) (PP-LOC (IN:[1528..1530] in) (NP (NNS:[1531..1541] carcinomas))) (PP-LOC (IN:[1542..1544] in) (NP (JJ:[1545..1552] Central) (NNP:[1553..1559] Europe)))) (VP (VBZ:[1560..1562] is) (ADJP-PRD (RB:[1563..1566] not) (JJ:[1567..1576] different) (PP (IN:[1577..1581] from) (NP (NP (DT:[1582..1585] the) (NNS:[1586..1597] frequencies)) (VP (VBN:[1598..1603] found) (NP (-NONE-:[1603..1603] *)) (PP (IN:[1605..1607] in) (NP (NP (JJ:[1608..1613] other) (NNS:[1614..1619] parts)) (PP (IN:[1620..1622] of) (NP (DT:[1623..1626] the) (NN:[1627..1632] world))))))))))))) (.:[1632..1633] .))) ;sentence 12 Span:1634..1774 ;The homogeneous incidence of K-ras mutation does not seem to be related to ;ethnic factors, dietary habits, or the composition of the diet. ;[1663..1668]:gene-rna:"K-ras" (SENT (S (NP-SBJ-1 (NP (DT:[1634..1637] The) (JJ:[1638..1649] homogeneous) (NN:[1650..1659] incidence)) (PP (IN:[1660..1662] of) (NP (NN:[1663..1668] K-ras) (NN:[1669..1677] mutation)))) (VP (VBZ:[1678..1682] does) (RB:[1684..1687] not) (VP (VB:[1688..1692] seem) (S (NP-SBJ-2 (-NONE-:[1692..1692] *)) (VP (TO:[1693..1695] to) (VP (VB:[1696..1698] be) (VP (JJ:[1699..1706] related) (NP-2 (-NONE-:[1706..1706] *)) (PP-CLR (TO:[1707..1709] to) (NP (NP (JJ:[1710..1716] ethnic) (NNS:[1717..1724] factors)) (,:[1724..1725] ,) (NP (JJ:[1726..1733] dietary) (NNS:[1734..1740] habits)) (,:[1740..1741] ,) (CC:[1742..1744] or) (NP (NP (DT:[1745..1748] the) (NN:[1749..1760] composition)) (PP (IN:[1761..1763] of) (NP (DT:[1765..1768] the) (NN:[1769..1773] diet)))))))))))) (.:[1773..1774] .))) ;section 13 Span:1778..1823 ;PMID: 10510729 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1778..1782] PMID) (::[1782..1783] :) (CD:[1784..1792] 10510729) (IN:[1793..1794] -LSB-) (NNP:[1794..1800] PubMed) (HYPH:[1801..1802] -) (JJ:[1803..1810] indexed) (IN:[1811..1814] for) (NNP:[1815..1823] MEDLINE-RSB-)))